Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
March 14, 2024 08:00 ET
|
Recce Pharmaceuticals
The next cohort of healthy subjects dosed at 3,000mg over 20 minutes, with the remaining subjects to be dosed over the coming daysRECCE® 327 now tested at four infusion times, achieving these...
Recce Pharmaceuticals to Present at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting
March 13, 2024 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, March 13, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced a...
Recce Pharmaceuticals Receives AUD $11.17 Million Research and Development (R&D) Advance
March 12, 2024 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, March 12, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced...
Recce Pharmaceuticals Continues Strategic Partnership with Murdoch Children’s Research Institute
February 29, 2024 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced...
Recce Pharmaceuticals Announces Expansion of Phase I/II Trial of RECCE® 327 for the Treatment of Diabetic Foot Infections
February 27, 2024 08:00 ET
|
Recce Pharmaceuticals
Independent Safety Committee unanimously agrees that the Phase I/II trial is safe, well tolerated, and fit for expanded accessStudy achieving primary endpoints of safety, tolerability, and efficacy by...
Recce Pharmaceuticals Establishes Strategic Partnership in South-East Asia to Accelerate Clinical Program
February 07, 2024 08:00 ET
|
Recce Pharmaceuticals
Memorandum of Understanding (MoU) with leading Indonesian biomedical company PT Etana BiotechnologiesMoU aims to facilitate late-stage clinical trials in Indonesia, supporting the Indonesian...
Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE® 327 for the Treatment of Diabetic Foot Infections
January 23, 2024 08:00 ET
|
Recce Pharmaceuticals
Phase I/II trial assessing the safety and efficacy of RECCE® 327 (R327), a broad-spectrum anti-infective as a topical treatment, met all primary endpointsR327 was well-tolerated in all patients,...
Recce Pharmaceuticals Awarded AusIndustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program
December 19, 2023 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced it was awarded...
Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 Against Gonorrhea
December 18, 2023 08:00 ET
|
Recce Pharmaceuticals
Preclinical data continues to demonstrate RECCE® 327’s significant bactericidal activity against Neisseria gonorrhoeae (N. gonorrhoeae), with a 4-log (99.99%) and 3.5-log (>99.9%) reductionN....
Recce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-Infectives
November 27, 2023 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the...